Shares of Apogee Therapeutics, Inc. (APGE) surged after the company reported positive 52-week Phase 2 data for its lead drug candidate in atopic dermatitis.
The stock is currently trading at $78.78, up $12.74 or 19.24%, on the Nasdaq. It opened at $76.75 after closing the previous session at $66.04. The stock has traded between $26.20 and $84.56 over the past 52 weeks.
Apogee Therapeutics said its Phase 2 APEX Part A study showed durable and deepening responses for zumilokibart (APG777) with both 3-month and 6-month dosing regimens over 52 weeks. The study demonstrated that 75% to 85% of patients maintained EASI-75, while 78% to 86% achieved vIGA 0/1, indicating strong and sustained disease control.
The treatment was well tolerated, with a safety profile consistent with other therapies in its class.
The company expects Part B induction data in the second quarter of 2026 and plans to initiate Phase 3 trials in the second half of 2026, with a potential commercial launch targeted for 2029, subject to regulatory approval.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.